<DOC>
	<DOCNO>NCT00623870</DOCNO>
	<brief_summary>This study determine maximum tolerate dose RO5045337 optimal associate 4 weekly dosing schedule RO5045337 , administer monotherapy patient hematologic neoplasm . A first cohort patient receive start dose 20mg/m2/day orally , daily 10 day 28 day cycle . Subsequent cohort patient receive dose escalation , possible change dose schedule , base tolerability pharmacokinetic knowledge gain prior treatment cohort . Different formulation RO5045337 test food effect evaluate . The anticipated time study treatment disease progression intolerable toxicity .</brief_summary>
	<brief_title>A Study RO5045337 RG7112 Patients With Hematologic Neoplasms .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Adult patient , &gt; =18 year age Acute myeloid leukemia , acute lymphocytic leukemia , chronic myelogenous leukemia blast phase , refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma Relapsed refractory approved therapy , viable alternative therapy available ECOG performance status 02 Patients receive agent therapy treat malignancy Preexisting gastrointestinal disorder may interfere absorption drug Clinically significant cardiovascular disease Pregnant lactate woman HIVpositive patient receive combination antiretroviral therapy Amendment J onward patient food effect evaluation subsequent patient dose high fat/high calorie meal find optimal : Patients allergy ingredient define liquid supplement and/or inability tolerate high fat/high calorie meal twice daily schedule RO5045337 dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>